ZA200104621B - Purification of Echinocandin cyclopeptide compounds. - Google Patents
Purification of Echinocandin cyclopeptide compounds. Download PDFInfo
- Publication number
- ZA200104621B ZA200104621B ZA200104621A ZA200104621A ZA200104621B ZA 200104621 B ZA200104621 B ZA 200104621B ZA 200104621 A ZA200104621 A ZA 200104621A ZA 200104621 A ZA200104621 A ZA 200104621A ZA 200104621 B ZA200104621 B ZA 200104621B
- Authority
- ZA
- South Africa
- Prior art keywords
- acetic acid
- product
- aldehyde
- echinocandin
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 37
- 108010049047 Echinocandins Proteins 0.000 title claims description 21
- 238000000746 purification Methods 0.000 title description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 141
- 238000000034 method Methods 0.000 claims abstract description 63
- 230000008569 process Effects 0.000 claims abstract description 37
- 238000000855 fermentation Methods 0.000 claims abstract description 27
- 230000004151 fermentation Effects 0.000 claims abstract description 27
- 239000000047 product Substances 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 239000006227 byproduct Substances 0.000 claims abstract description 20
- 125000003277 amino group Chemical group 0.000 claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 108010069514 Cyclic Peptides Proteins 0.000 claims abstract description 13
- 102000001189 Cyclic Peptides Human genes 0.000 claims abstract description 13
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000012501 chromatography medium Substances 0.000 claims abstract description 10
- 229920005989 resin Polymers 0.000 claims description 18
- 239000011347 resin Substances 0.000 claims description 18
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 14
- 239000011148 porous material Substances 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- 229920000620 organic polymer Polymers 0.000 claims description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 4
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical group C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- UJTTUOLQLCQZEA-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(4-hydroxybutyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCCO)C3=CC=CC=C3C2=C1 UJTTUOLQLCQZEA-UHFFFAOYSA-N 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims 1
- 235000010633 broth Nutrition 0.000 abstract description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 83
- 238000010828 elution Methods 0.000 description 31
- -1 Sporiofungin A Proteins 0.000 description 19
- 229910004373 HOAc Inorganic materials 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000003960 organic solvent Substances 0.000 description 8
- FAUOJMHVEYMQQG-HVYQDZECSA-N echinocandin B Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](C)O)=CC=C(O)C=C1 FAUOJMHVEYMQQG-HVYQDZECSA-N 0.000 description 7
- 108010062092 echinocandin B Proteins 0.000 description 7
- 229930014626 natural product Natural products 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- 230000020176 deacylation Effects 0.000 description 6
- 238000005947 deacylation reaction Methods 0.000 description 6
- 239000003607 modifier Substances 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- CMJCEVKJYRZMIA-UHFFFAOYSA-M thallium(i) iodide Chemical compound [Tl]I CMJCEVKJYRZMIA-UHFFFAOYSA-M 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- WLGDAKIJYPIYLR-UHFFFAOYSA-N octane-1-sulfonic acid Chemical compound CCCCCCCCS(O)(=O)=O WLGDAKIJYPIYLR-UHFFFAOYSA-N 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 229940001584 sodium metabisulfite Drugs 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- KAPLTEIQCKDUAT-UHFFFAOYSA-N ac1la431 Chemical compound N1C(=O)C2CC(O)CN2C(=O)C(C(C)O)NC(=O)C(NC(=O)CCCCCCCCCCCCCCC)CC(O)C(O)NC(=O)C2C(O)C(C)CN2C(=O)C(C(O)CC(N)=O)NC(=O)C1C(O)C(O)C1=CC=C(O)C(OS(O)(=O)=O)=C1 KAPLTEIQCKDUAT-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 241000187840 Actinoplanes utahensis Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 241000288147 Meleagris gallopavo Species 0.000 description 1
- WUPSJTQKGFMDON-UHFFFAOYSA-N Mulundocandin Natural products N1C(=O)C2CC(O)CN2C(=O)C(C(C)O)NC(=O)C(NC(=O)CCCCCCCCCCC(C)CC)CC(O)C(O)NC(=O)C2C(O)C(C)CN2C(=O)C(CO)NC(=O)C1C(O)C(O)C1=CC=C(O)C=C1 WUPSJTQKGFMDON-UHFFFAOYSA-N 0.000 description 1
- WUPSJTQKGFMDON-FUMJLYDLSA-N N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-3-(hydroxymethyl)-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-12-methyltetradecanamide Chemical compound CCC(C)CCCCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)C(O)c1ccc(O)cc1 WUPSJTQKGFMDON-FUMJLYDLSA-N 0.000 description 1
- CWLQUGTUXBXTLF-UHFFFAOYSA-N N-methyl-L-proline monohydrate Natural products CN1CCCC1C(O)=O CWLQUGTUXBXTLF-UHFFFAOYSA-N 0.000 description 1
- CWLQUGTUXBXTLF-YFKPBYRVSA-N N-methylproline Chemical compound CN1CCC[C@H]1C(O)=O CWLQUGTUXBXTLF-YFKPBYRVSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010045495 WF 11899A Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000002431 aminoalkoxy group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 108010062096 echinocandin C Proteins 0.000 description 1
- NZZDHXBKVFENNY-YBPCKFEPSA-N echinocandin c Chemical compound C([C@@H](O)[C@H]1C(=O)N[C@H](C(=O)N2C[C@H](C)[C@H](O)[C@H]2C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N1)[C@@H](C)O)=O)NC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](C)O)C1=CC=C(O)C=C1 NZZDHXBKVFENNY-YBPCKFEPSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108010084578 mulundocandin Proteins 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- OGNAOIGAPPSUMG-UHFFFAOYSA-N spiro[2.2]pentane Chemical compound C1CC11CC1 OGNAOIGAPPSUMG-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000010891 toxic waste Substances 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11152498P | 1998-12-09 | 1998-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200104621B true ZA200104621B (en) | 2002-06-06 |
Family
ID=22339024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200104621A ZA200104621B (en) | 1998-12-09 | 2001-06-06 | Purification of Echinocandin cyclopeptide compounds. |
Country Status (17)
Country | Link |
---|---|
US (1) | US6506726B1 (fr) |
EP (1) | EP1137663B1 (fr) |
JP (1) | JP2003511345A (fr) |
KR (1) | KR20010101151A (fr) |
CN (1) | CN1337968A (fr) |
AT (1) | ATE338059T1 (fr) |
AU (1) | AU766091B2 (fr) |
BR (1) | BR9916101A (fr) |
CA (1) | CA2353930A1 (fr) |
DE (1) | DE69933046T2 (fr) |
DK (1) | DK1137663T3 (fr) |
ES (1) | ES2272096T3 (fr) |
IL (1) | IL143563A0 (fr) |
PT (1) | PT1137663E (fr) |
RU (1) | RU2001118849A (fr) |
WO (1) | WO2000034315A2 (fr) |
ZA (1) | ZA200104621B (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6743777B1 (en) * | 1992-03-19 | 2004-06-01 | Eli Lilly And Company | Cyclic peptide antifungal agents and process for preparation thereof |
AU771727B2 (en) | 1999-03-03 | 2004-04-01 | Eli Lilly And Company | Processes for making pharmaceutical oral ECB formulations and compositions |
ATE338060T1 (de) | 1999-03-03 | 2006-09-15 | Lilly Co Eli | Bildung und anionenaustausch von inneren kristallinen ammoniumsalzen des echinocandins b |
WO2000051564A1 (fr) * | 1999-03-03 | 2000-09-08 | Eli Lilly And Company | Formulations pharmaceutiques d'echinocandine contenant des tensioactifs formant des micelles |
KR20020003864A (ko) | 1999-03-03 | 2002-01-15 | 피터 지. 스트링거 | 에키노칸딘/탄수화물 착물 |
US6991800B2 (en) * | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
JP5112060B2 (ja) * | 2004-06-29 | 2013-01-09 | リライアンス ライフ サイエンシーズ プライベイト リミテッド | ウイルス安全性生物学的流体の調製のための方法 |
DE102004060750A1 (de) | 2004-12-15 | 2006-07-13 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Deacylierung von Lipopeptiden |
TW200826957A (en) * | 2006-10-16 | 2008-07-01 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Purification processes for echinocandin-type compounds |
US9394340B2 (en) | 2009-03-24 | 2016-07-19 | Cadila Healthcare Limited | Purification process for lipopeptides |
CN102219832B (zh) * | 2010-04-15 | 2013-08-21 | 上海天伟生物制药有限公司 | 一种氮杂环六肽或其盐的纯化方法 |
CN102336817B (zh) * | 2010-07-16 | 2016-06-15 | 浙江震元制药有限公司 | 棘球白素b母核的分离方法 |
JP6000254B2 (ja) * | 2010-09-29 | 2016-09-28 | 上海天偉生物制薬有限公司 | 環状リポペプチド化合物又はその塩の精製方法 |
AU2011307733B2 (en) * | 2010-09-30 | 2015-03-26 | Shanghai Techwell Biopharmaceutical Co., Ltd. | Method for purifying cyclic lipopeptide or salt thereof |
CN102153616A (zh) * | 2010-12-27 | 2011-08-17 | 浙江海正药业股份有限公司 | 一种环己肽类化合物及其盐的分离纯化方法 |
HUE036778T2 (hu) | 2011-03-03 | 2018-07-30 | Cidara Therapeutics Inc | Gombaellenes szerek és alkalmazásuk |
AU2012244435B2 (en) | 2011-04-20 | 2017-06-15 | Xellia Pharmaceuticals Aps | Method for purification of Micafungin |
CN102952178B (zh) * | 2011-08-24 | 2016-04-27 | 华北制药集团新药研究开发有限责任公司 | 一种高纯度棘白霉素类化合物的制备方法 |
CN104507309B (zh) | 2012-03-19 | 2017-05-03 | 奇达拉治疗公司 | 用于棘白菌素类化合物的给药方案 |
CN103483427A (zh) * | 2012-06-09 | 2014-01-01 | 浙江海正药业股份有限公司 | 一种棘白菌素类化合物的纯化方法 |
CN103910783B (zh) * | 2014-04-23 | 2016-07-06 | 华北制药集团新药研究开发有限责任公司 | 一种高纯度棘白霉素b母核的制备方法 |
PL3058958T3 (pl) | 2015-02-23 | 2019-02-28 | Selectchemie Ag | Kompozycja anidulafunginy |
CN108883152A (zh) | 2016-01-08 | 2018-11-23 | 奇达拉治疗公司 | 防止和治疗肺孢子虫感染的方法 |
CN109154603A (zh) | 2016-03-16 | 2019-01-04 | 奇达拉治疗公司 | 用于治疗真菌感染的给药方案 |
CN106248857A (zh) * | 2016-07-15 | 2016-12-21 | 广西医科大学 | 利用薄层层析快速检测植物环肽的方法 |
EP3651801A4 (fr) | 2017-07-12 | 2021-04-07 | Cidara Therapeutics, Inc. | Compositions et méthodes pour le traitement d'infections fongiques |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4293482A (en) | 1979-12-13 | 1981-10-06 | Eli Lilly And Company | A-30912A Nucleus |
US4293489A (en) | 1979-12-13 | 1981-10-06 | Eli Lilly And Company | Derivatives of A-30912A nucleus |
US4304716A (en) | 1979-12-13 | 1981-12-08 | Eli Lilly And Company | S 31794/F-1 Nucleus |
US4320052A (en) | 1979-12-13 | 1982-03-16 | Eli Lilly And Company | Derivatives of A-30912A nucleus |
EP0294990A3 (fr) | 1987-06-10 | 1990-05-09 | Eli Lilly And Company | Procédé de purification chromatographique |
US4874843A (en) | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
DK173802B1 (da) | 1988-09-12 | 2001-11-05 | Merck & Co Inc | Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner |
US5166135A (en) | 1988-09-12 | 1992-11-24 | Merck & Company, Inc. | Method for the control of pneumocystis carinii |
US5310726A (en) | 1990-03-19 | 1994-05-10 | Merck & Co., Inc. | Lipopeptide compounds |
ES2089133T3 (es) | 1990-06-07 | 1996-10-01 | Lilly Co Eli | Desacilasa de lipopeptidos. |
IL98506A (en) | 1990-06-18 | 1996-09-12 | Fujisawa Pharmaceutical Co | Peptides, of antibiotics, processes for their preparation and pharmaceutical preparations containing them |
MY136593A (en) | 1992-03-19 | 2008-10-31 | Lilly Co Eli | Cyclic peptide antifungal agents and process for preparation thereof |
US5965525A (en) | 1992-03-19 | 1999-10-12 | Eli Lilly And Company | Cyclic peptide antifungal agents |
US5541160A (en) | 1994-04-04 | 1996-07-30 | Merck & Co., Inc. | Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use |
US5646111A (en) | 1995-04-07 | 1997-07-08 | Eli Lilly And Company | Cyclic peptide antifungal Agents |
US5618787A (en) | 1995-05-26 | 1997-04-08 | Eli Lilly And Company | Cyclic peptide antifungal agents |
US5652213A (en) | 1995-05-26 | 1997-07-29 | Eli Lilly And Company | Cyclic peptide antifungal agents |
US5786325A (en) | 1995-05-26 | 1998-07-28 | Eli Lilly And Company | Cyclic peptide antifungal agents and methods of making and using |
US5629290A (en) | 1995-05-26 | 1997-05-13 | Eli Lilly And Company | Cyclic peptide antifungal agents |
US5629289A (en) | 1995-07-25 | 1997-05-13 | Eli Lilly And Company | Cyclic peptide antifungal agents |
JP2001503015A (ja) | 1996-02-01 | 2001-03-06 | イーライ・リリー・アンド・カンパニー | 環状ペプチド抗真菌剤 |
US5696084A (en) | 1996-08-16 | 1997-12-09 | Abbott Laboratories | Amino-lipopetide antifungal agents |
AU8687798A (en) | 1997-08-04 | 1999-02-22 | Eli Lilly And Company | Cyclic peptide antifungal agents |
EP0931834A3 (fr) | 1997-12-23 | 2002-06-26 | Eli Lilly And Company | Domaine de liaison d'echinocandinl de la 1,3-beta-glucane synthase |
US6323176B1 (en) | 1998-02-25 | 2001-11-27 | Eli Lilly And Company | Cyclic peptide antifungal agents |
ES2233070T3 (es) | 1998-08-20 | 2005-06-01 | ELI LILLY & COMPANY | Sintesis de analogos peptidicos ciclicos modificados en el anillo. |
EP1107982B1 (fr) | 1998-08-28 | 2004-05-19 | Eli Lilly & Company | Complexes reversibles du bore de peptides cycliques contenant des groupes 1,2-(cis)-diol |
AU1517900A (en) | 1998-10-28 | 2000-05-15 | Eli Lilly And Company | Photochemical process for making 1-deoxy-2-keto derivatives |
WO2000035945A1 (fr) | 1998-12-16 | 2000-06-22 | Eli Lilly And Company | Agents antifongiques de peptide cyclique possedant un substituant sucre |
CA2354056A1 (fr) | 1998-12-16 | 2000-06-22 | James Andrew Jamison | Agents antifongiques de peptide cyclique |
AU771727B2 (en) | 1999-03-03 | 2004-04-01 | Eli Lilly And Company | Processes for making pharmaceutical oral ECB formulations and compositions |
WO2000051564A1 (fr) | 1999-03-03 | 2000-09-08 | Eli Lilly And Company | Formulations pharmaceutiques d'echinocandine contenant des tensioactifs formant des micelles |
ATE338060T1 (de) | 1999-03-03 | 2006-09-15 | Lilly Co Eli | Bildung und anionenaustausch von inneren kristallinen ammoniumsalzen des echinocandins b |
KR20020003864A (ko) | 1999-03-03 | 2002-01-15 | 피터 지. 스트링거 | 에키노칸딘/탄수화물 착물 |
-
1999
- 1999-12-08 CA CA002353930A patent/CA2353930A1/fr not_active Abandoned
- 1999-12-08 AT AT99965156T patent/ATE338059T1/de not_active IP Right Cessation
- 1999-12-08 PT PT99965156T patent/PT1137663E/pt unknown
- 1999-12-08 JP JP2000586757A patent/JP2003511345A/ja not_active Abandoned
- 1999-12-08 US US09/857,924 patent/US6506726B1/en not_active Expired - Fee Related
- 1999-12-08 DK DK99965156T patent/DK1137663T3/da active
- 1999-12-08 IL IL14356399A patent/IL143563A0/xx unknown
- 1999-12-08 RU RU2001118849/04A patent/RU2001118849A/ru not_active Application Discontinuation
- 1999-12-08 WO PCT/US1999/029008 patent/WO2000034315A2/fr active IP Right Grant
- 1999-12-08 EP EP99965156A patent/EP1137663B1/fr not_active Expired - Lifetime
- 1999-12-08 AU AU31132/00A patent/AU766091B2/en not_active Ceased
- 1999-12-08 ES ES99965156T patent/ES2272096T3/es not_active Expired - Lifetime
- 1999-12-08 CN CN99815515A patent/CN1337968A/zh active Pending
- 1999-12-08 DE DE69933046T patent/DE69933046T2/de not_active Expired - Fee Related
- 1999-12-08 BR BR9916101-0A patent/BR9916101A/pt not_active IP Right Cessation
- 1999-12-08 KR KR1020017007161A patent/KR20010101151A/ko not_active Application Discontinuation
-
2001
- 2001-06-06 ZA ZA200104621A patent/ZA200104621B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20010101151A (ko) | 2001-11-14 |
IL143563A0 (en) | 2002-04-21 |
AU766091B2 (en) | 2003-10-09 |
JP2003511345A (ja) | 2003-03-25 |
AU3113200A (en) | 2000-06-26 |
EP1137663B1 (fr) | 2006-08-30 |
WO2000034315A2 (fr) | 2000-06-15 |
DE69933046D1 (de) | 2006-10-12 |
DK1137663T3 (da) | 2007-01-08 |
US6506726B1 (en) | 2003-01-14 |
DE69933046T2 (de) | 2007-09-13 |
EP1137663A2 (fr) | 2001-10-04 |
WO2000034315A8 (fr) | 2000-10-26 |
CN1337968A (zh) | 2002-02-27 |
ES2272096T3 (es) | 2007-04-16 |
WO2000034315A3 (fr) | 2000-12-28 |
RU2001118849A (ru) | 2003-08-10 |
ATE338059T1 (de) | 2006-09-15 |
PT1137663E (pt) | 2006-12-29 |
BR9916101A (pt) | 2002-06-04 |
CA2353930A1 (fr) | 2000-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6506726B1 (en) | Purification of Echinocandin cyclopeptide compounds | |
JP4063497B2 (ja) | エキノカンジンアンモニウム塩結晶の形成およびアニオン交換 | |
SK283115B6 (sk) | Spôsob výroby azacyklohexapeptidových zlúčenín a medziprodukt | |
US4994555A (en) | Process for recovery of glycopeptidic antibiotics | |
JP2013509365A (ja) | コリスチンの精製方法および精製コリスチン成分 | |
Berkecz et al. | LC enantioseparation of β-lactam and β-amino acid stereoisomers and a comparison of macrocyclic glycopeptide-and β-cyclodextrin-based columns | |
AU613640B2 (en) | Chromatographic purification process | |
EP0146822B1 (fr) | Procédé chimique pour la préparation de l'antibiotique L 17054 | |
AU2004200026A1 (en) | Purification of echinocandin cyclopeptide compounds | |
MXPA01005688A (en) | Purification of echinocandin cyclopeptide compounds | |
MXPA01008787A (en) | Formation and anion-exchange of crystalline echinocandin ammonium salts | |
US5936074A (en) | Teicoplanin deacylation process and product | |
AU2004200741A1 (en) | Formation and anion-exchange of crystalline echinocandin ammonium salts |